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Abstract
Purpose—Huntington disease (HD) is an incurable terminal disease. Thus, end of life (EOL)
concerns are common in these individuals. A quantitative measure of EOL concerns in HD would
enable a better understanding of how these concerns impact health-related quality of life.
Therefore, we developed new measures of EOL for use in HD.
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Methods—An EOL item pool of 45 items was field tested in 507 individuals with prodromal or
manifest HD. Exploratory and confirmatory factor analyses (EFA and CFA, respectively) were
conducted to establish unidimensional item pools. Item response theory (IRT) and differential item
functioning analyses were applied to the identified unidimensional item pools to select the final
items.
Results—EFA and CFA supported two separate unidimensional sets of items: Concern with
Death and Dying (16 items), and Meaning and Purpose (14 items). IRT and DIF supported the
retention of 12 Concern with Death and Dying items and 4 Meaning and Purpose items. IRT data
supported the development of both a computer adaptive test (CAT) and a 6-item, static short-form
for Concern with Death and Dying.
Conclusions—The HDQLIFE Concern with Death and Dying CAT and corresponding 6-item
short form, and the 4-item calibrated HDQLIFE Meaning and Purpose Scale demonstrate excellent
Qual Life Res. Author manuscript; available in PMC 2017 October 01.
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psychometric properties. These new measures have the potential to provide clinically meaningful
information about end of life preferences and concerns to clinicians and researchers working with
individuals with HD. In addition, these measures may also be relevant and useful for other
terminal conditions.
Keywords
Health-related quality of life; Neuro-QoL; PROMIS; HDQLIFE; Huntington disease; end of life;
patient reported outcome (PRO)
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Huntington disease (HD) is an autosomal dominant neurodegenerative disease that causes
motor, behavioral, and cognitive impairments; symptoms typically begin in midlife and
progress to death within 20 years [1; 2]. End of life concerns may begin when patients
become aware of their at-risk status, and are magnified after predictive testing reveals a gene
mutation positive status, or after a clinical diagnosis of HD [3]. Experiences with the
progression of disease and death in other family members [4] impacts the perspectives of atrisk and affected individuals about their own end of life (EOL) [4] as well as health-related
quality of life (HRQOL) [3]. Individuals at-risk for HD, as well as those individuals across
the full range of the HD disease spectrum (including those with no symptoms to those in the
later stages of the disease), have identified EOL concerns as an important component of
HRQOL [3]. Specifically, qualitative research in individuals with HD has identified the
importance of EOL planning (including family planning, financial planning, and planning
for palliative care) and concerns about how EOL affects the entire family (both in watching
other family members suffer and die from this disease, as well as concerns about the burden
that their disease may place on other family members) as important components of HRQOL
[3]. A quantitative measure of EOL concerns in HD would facilitate our understanding of
their relevance to HRQOL, and of their sensitivity to treatments or interventions [5-9]. An
ideal HD-specific EOL measure should be appropriate for patients at all stages of the disease
process, from the pre-symptomatic or prodromal period, to the late stages when cognitive
decline may impact comprehension and judgment about EOL issues [10]. Such a tool could,
in turn, assist health care providers in initiating discussions about EOL decision-making,
help them to determine at what point patients would be most receptive to EOL discussions,
[11] and increase their understanding about how EOL beliefs change over the disease course
[12].

Author Manuscript

Several measures exist which were originally intended to measure HRQOL, but these
measures were either developed for use in other diseases such as cancer, (e.g., revised
Hospice Quality of Life Index [13]; Death and Dying Distress Scale [14; 15]; McGill
Quality of Life Questionnaire [16; 17]; QUAL-EC [18]) or are overly generic (e.g.,
CANHELP Lite [19]; EOL-PRO [20]; the Missoula-VITAS quality of life index [21];
Palliative Patients’ Dignity Scale [22]; Patient Needs Assessment in Palliative Care [23];
Valuation of Life [24]; QUAL-E [25]). These tools do not capture EOL concerns specific to
HD (e.g., concerns related to watching other family members suffer from and die from the
disease; concerns about the burden of having HD places on other family members; concerns
about your children inheriting the disease from you; the fact that there is a gene test that can
accurately predict who will get symptoms, but not when), take too long to implement (i.e.,
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the CANHELP [26]), and/or include substandard psychometric properties [6-8]. In addition,
all of these measures neglect to address concerns about EOL impact on HRQOL during the
earlier stages of a neurodegenerative disease.
To address these shortcomings, this study focused on developing new measures that could
capture the EOL concerns reported by individuals with HD, their caregivers, and clinical
providers [3]. Specifically, we used state-of-the-science psychometric methods to create
calibrated item banks that are comprised of numerous items that allow for administration as
either a computerized adaptive test (CAT) or as a static short form; administration options
that provide accurate measurement with low response burden [27]. Below, we highlight the
development of two new measures of EOL concerns, which are part of a new measurement
system, the HDQLIFE [28].

Author Manuscript

Methods

Author Manuscript

Individuals with prodromal or manifest HD were invited to participate in this study.
Participants were at least 18 years old, able to read and understand English, and had either a
positive test for the CAG expansion for HD (HD is a caused by an expansion of CAG
repeats in the HD gene [HTT]) and/or a clinical diagnosis of HD, and had the ability to
provide informed consent. In cases where there were concerns about the cognitive capacity
of a potential participant, the Orientation Log – HD (O-Log-HD) was administered. The OLog-HD was adapted from the Orientation Log (O-Log) [29] and provides an assessment of
mental status; possible scores range from 0-30 and participants with scores < 25 were not
eligible to participate in the study. Participants were recruited from several specialized HD
treatment centers (the University of Michigan, the University of Iowa, the University of
California-Los Angeles, Indiana University, Johns Hopkins University, Rutgers University,
Struthers Parkinson's Center, and Washington University), through electronic medical
records [30], the National Research Roster for Huntington's Disease, and articles/
advertisements in HD-specific newsletters and websites. Additionally, the majority of the
prodromal HD participants in this study were recruited through the Predict-HD study
[31-33], a longitudinal prospective study (over 30 sites worldwide), examining the clinical
markers of prediagnostic (i.e., prodromal) HD; this cohort includes over 700, wellcharacterized individuals with prodromal HD.
HDQLIFE End of Life Item Pool

Author Manuscript

Sixty-nine items that examined concerns with EOL were developed through an iterative
process [28]. Item content was derived in conjunction with the Neuro-QoL project [34], and
was comprised of literature reviews [34; 35], as well as focus group data in HD, and expert
input [3]. Items were refined through expert review, translatability review, and cognitive
interviews with individuals with HD following established methodology [36]; Figure 1
documents this iterative process. The final item pool was comprised of 45 items.
Participant Characterization
The Total Functional Capacity (TFC) scale [37] from the United Huntington's Disease
Rating Scales (UHDRS) [38] was administered to all participants. The TFC is a clinician
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administered 5-item scale designed to evaluate day-to-day functioning across the domains of
occupation, finances, domestic chores, activities of daily living, and care level. Scores range
from 0 to 13 with higher scores indicating better functioning. Participants with an HD
diagnosis were classified as either early-stage (TFC sum scores of 7-13; Stages 1 and 2) or
later-stage HD (TFC sum scores of 0-6; Stages 3-5).
Analysis Approach

Author Manuscript

Unidimensionality—Factor analyses were used to establish the unidimensionality of the
item pool. First, our sample was randomly divided into two data sets. Exploratory factor
analysis (EFA) with a PROMAX rotation was used to determine number of factors within
the item pool according to Eigenvalues (> 1) and the number of factors before the break in
the scree plot. Item loadings were used to determine items and their associated factor
(criterion > 0.4). Confirmatory factor analysis (CFA) for robust weighted least square
estimation for ordinal data was then conducted to confirm the factor structure determined
based on the EFA results [39; 40]. Good fit was established as a comparative fit index (CFI)
> 0.90, Tucker Lewis Index (TLI) > 0.95, root mean square error of approximation
(RMSEA) <0.1 [41-44], and residual correlations < .15 (i.e., maintain local independence)
[45-47]; fit indices meet established standards for CFA when it is applied to PRO
development [47]. In addition, Cronbach's alpha was examined to determine acceptable
reliability of the measure (i.e., > .80). EFA and CFA analyses were conducted using MPLUS
6.11 [48].

Author Manuscript

Item Response Theory (IRT) Anlayses—The finalized item pools were then calibrated
using Samejima's graded response model (GRM) [49]; these analyses were conducted in
IRTPRO 2.1 [50]. This analysis estimated item threshold and item slope parameters, which
were then used to calculate information functions at the level of individual items and at the
level of the entire item bank, to characterize measurement precision on the measurement
continuum at both item and scale levels. Differential item functioning (DIF) was used to
evaluate stability of measurement properties for each individual item between sub-groups by
using IRT scaled-score based ordinal logistic regression [51]. DIF analyses were conducted
using the LORDIF package within R (Version 0.3-2) [52]. DIF was evaluated on gender, age
(≤ 40 vs. >40 years; ≤50 vs. >50 years), and education (high school graduate or less vs. >
high school). Items with DIF (non-negligible DIF criterion: R2 > 0.02 and p<.01) were
discussed by the study team and were candidates for exclusion. Firestar CAT simulation
software [53] was used to conduct simulation analyses to: 1) determine the number of items
administered by the CAT for different ability levels for the trait; and 2) examine the
relationship between the simulated CAT score and scores derived using all items in the bank.

Author Manuscript

Other Demographic Comparisons—We collected demographic information on age,
gender, education, and race. Pearson correlations between the new HDQLIFE measures and
demographic variables (i.e., age and education) were examined. In addition, an independent
sample t test was conducted to determine if there were significant gender differences for
these HDQLIFE measures.
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Sample Size Considerations—Study sample size was determined based on sample size
requirements for IRT, DIF, EFA and CFA analyses. When using Graded Response Models
(GRM), larger sample sizes produce more stable parameter estimation [49; 54]. In general,
established standards suggest that a minimum of 5-10 individuals are needed for every item
within an item pool in order to establish stable parameter estimates [55-57]; thus 500
individuals were needed for reliable item response theory (IRT) calibration data. Established
standards for differential item functioning (DIF) analyses (an indication of item bias)
suggest that at least 200 participants are needed within each condition; considering these
parameters, sampling stratification targeted age (< 40 vs. ≥ 40 and <50 vs. ≥ 50), gender
(male vs. female), and education (< high school vs. ≥ high school]) [58]. Finally, EFA and
CFA analyses recommend the inclusion of ~5 people per item analyzed [55; 57]; thus 250
individuals were needed for EFA and CFA analyses, respectively (5 individuals for ~50
items per item pool).

Author Manuscript

Results

Author Manuscript

Five hundred seven (507) individuals with prodromal or manifest HD participated in this
study. Participants were sampled to represent the entire continuum of HD symptomatology;
196 individuals had prodromal HD (CAG > 35, but did not yet have an HD clinical
diagnosis), 193 had early-stage HD (sum scores of 7-13 on the TFC), 117 had later-stage
HD (sum scores of 0-6 on the TFC), and 1 participant was not classifiable. Participants
ranged in age from 18-81 years (M = 49.01, SD = 13.21) and 40.8% of participants were
male. Significant differences were seen for age (as symptoms are progressive with age), F
(2, 503) = 47.360, p< .0001, with individuals who were prodromal (M = 42.60, SD = 12.04)
being significantly younger than the early-HD group (M = 51.91, SD = 12.41) and the lateHD group (M = 55.07, SD = 11.89). The early-HD group was also significantly younger
than the late-HD group. Groups did not differ on gender, Χ2 (2, N = 506) = 3.193, p = .20.
The majority of participants were Caucasian (96.4%); 2.0% were African American, 1.4%
were classified as “other,” and 0.2% were unknown. Participants’ education ranged from 4
to 26 years (M = 15.06, SD = 2.88). While there were group differences in education, F (2,
501) = 14.781, p< .0001, these differences were small; early- (M = 14.74, SD = 2.78) and
late-HD (M = 14.22, SD = 2.62) had 1 to 1.5 years less education relative to the prodromal
HD group (M = 15.88 years, SD = 2.94).
Unidimensionality

Author Manuscript

Exploratory Factor Analyses (EFA)—Findings based on a random sample of 254
individuals indicated that the data could largely be explained by 4 factors (Table 1); the first
factor included 14 items that generally represented meaning and purpose; the second factor
included only two highly-similar items concerning family members who had died of HD; the
third factor included 12 items that generally represented anxieties and worries concerning
death; the fourth factor included 16 items that generally represented thoughts concerning
death and dying; and finally, 1 item did not load on any of the four factors. Because of the
spurious nature of the second factor, and the fact that there is an existing PROMIS measure
concerning anxiety, we elected to focus on developing measures that reflected meaning and
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purpose (factor 1) and death and dying (factor 4). For the remainder of analyses, we focused
solely on these two factors.
Confirmatory Factor Analysis (CFA)—Using the second random sample of 253
individuals, CFAs were conducted separately on each of the two subdomains (i.e., meaning
and purpose and death and dying) to confirm unidimensionality.
Meaning and Purpose—Content considerations and large residual correlations caused us
to reduce the number of items for this scale to 7 from 14 items. Results indicated that all 7
items examining meaning and purpose generally fit the data well; CFI = 0.99, TLI = 0.98,
RMSEA = 0.11, all r2 > .03. Additionally, all residual correlations were ≤ 0.11 and all itemtotal correlations were > 0.4. Cronbach's alpha for this measure was 0.84.

Author Manuscript

Death and Dying—Examination of all 16 items examining difficulties with death and
dying revealed 3 items with large residual correlations. These items were deleted resulting in
13 final items; all residual correlations were ≤ 0.15 for these items. These 13 items were
then examined using a 1 factor CFA; the analysis for these 13 items yielded a CFI = 0.97,
TLI = 0.96, RMSEA = 0.15, all r2 > .03. All item-total correlations were > 0.4. Cronbach's
alpha for this scale was 0.94.
IRT Analyses

Author Manuscript

Meaning and Purpose—The seven selected items were analyzed using graded response
model (GRM) [54], in accordance with PROMIS recommendations [50]. IRT parameter
estimates indicated slopes ranging from 0.84 to 4.75 and thresholds ranging from −3.26 to
1.78 (See Table 2). S-X2 model fit statistics were examined using IRTPRO; although 5 items
had misfit statistics (p < 0.05) they were included for further consideration. Information was
good (i.e., marginal reliability = 0.83), for scale scores between −3 and 0.5 (see Figure 2 for
the scale information function). No items showed DIF on age, gender, or education. Items
with slopes < 2.0, as well as misfit statistics, were omitted from the final item set (“I feel
comfortable talking about my death;” “I find meaning in my illness;” and “There are
important things that I still want to do with my life”). Thus, 4-items were retained for
inclusion in this scale and a static short form (instead of a computer adaptive test) was
developed.

Author Manuscript

Concern with Death and Dying—One item, “I feel in control of my life” was deleted
due to a poor slope (0.98). The remaining 12 items indicated slope parameters ranging from
1.48 to 4.57 and threshold parameters ranging from −0.98 to 3.65 (Table 3). Information was
good (i.e., reliability ≥ .80), for scale scores between −1.5 and 3.0 (see Figure 3 for the scale
information function). Although S-X2 indicated that 5 of the 12 items had misfit (p < 0.05);
these items were retained for further consideration. Marginal reliability was 0.91. DIF was
not found for age (<50 vs. ≥50 or <40 vs. ≥40), gender (male vs. female), or education
(some college and lower vs. college degree and higher). A 6-item calibrated Concern with
Death and Dying short form was then created based on information of slope parameters,
item characteristic curves, item information, and average item difficulty, as well as input
from HD and measurement development experts on clinical characteristics (e.g., items were
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selected that represent different important clinical components of concerns with death and
dying). Specifically, we balanced the psychometric considerations with clinical content to
ensure representativeness of the items that were selected for the short form.
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Simulation results showed that the average number of items administered to 10,000 virtual
respondents by the Firestar CAT simulation software was 7.02. The correlation between the
CAT scores and the full item-bank was 0.99, indicating that the CAT based on the Concern
with Death and Dying item bank can produce results that are very similar to those obtained
with administration of the entire 12-item set. Figure 4 shows the number of CAT items used
for different scale scores in standard deviation units: at −1 SD units, the CAT always used all
12 items in the item bank; at +1 and +2 SD units, the CAT always used the minimum
number of 4 items in the item bank; and at 3 SD units the CAT used all 12 items in the item
bank. Thus, the CAT simulation indicates that fewer items were needed to estimate scores
for individuals with greater concern with death and dying than for individuals with less
concern with death and dying.
Scoring of Short Forms
The IRT-scaled scores (theta) were converted into a standardized score utilizing a t score
(mean = 50, SD = 10; referenced to the HD population represented by the current sample);
see Table 4 and 5 for a summed score scale conversion table for the short forms for Meaning
and Purpose, and Concern with Death and Dying, respectively. Higher scores indicate more
of the construct (i.e., higher scores for Meaning and Purpose indicate greater meaning and
purpose in ones’ life, whereas higher scores on Concern with Death and Dying, indicate
greater concerns or preoccupation with death and dying).
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Other Demographic Comparisons
There was a small, but significant negative relationship between age and HDQLIFE Concern
with Death and Dying (r = −.12, p = .009); there was no relationship between age and
HDQLIFE Meaning and Purpose (r = .05, p = .24). Relationships between education and
HDQLIFE Concern with Death and Dying (r = .01, p = .76), and education and HDQLIFE
Meaning and Purpose (r = −.07, p = .10) were negligible. Independent samples t test
indicated that women (M = 50.92; SD = 9.39) report more Concern with Death and Dying
than men (M = 48.80; SD =8.24), t(493) = −2.59, p = .01; there were no differences between
men (M=49.46; SD = 9.28) and women (50.42; SD 8.97) for Meaning and Purpose, t(493) =
−1.16, p = .25.

Discussion
Author Manuscript

This paper presents the development of two new patient reported outcomes measures from
HDQLIFE [28] that evaluate end of life concerns in HD: Meaning and Purpose, and Concern
with Death and Dying. Analyses supported the development of a 4-item calibrated scale to
capture Meaning and Purpose, and an item bank that can be administered as either a CAT or
a 6-item short form to capture Concern with Death and Dying. These are the first measures
of EOL that have been developed specifically for use in HD and include the first CAT for
use in evaluating patient reported outcomes regarding EOL concerns. CAT allows for a
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much briefer approach towards assessment, in that only the most relevant items are
administered; item selection is based on the participants’ previous response. Furthermore,
these measures are scored using a t metric, with a mean of 50 and standard deviation of 10;
higher scores indicate more of the construct (i.e., higher scores for Meaning and Purpose
indicate greater meaning and purpose in ones’ life, whereas higher scores on Concern with
Death and Dying indicate greater concerns or preoccupation with death and dying). This
approach allows for an estimation of an individual's functioning relevant to the reference
group (in this case, other individuals with HD). For example, scores of 60 or greater on
Concern with Death and Dying indicate that the individual is more preoccupied with these
thoughts than 68.27% of people with HD. Scores above 70 indicate thoughts/preoccupation
with death and dying that exceed 95.45% of individuals with HD. Given the fact that talking
about these issues can be uncomfortable for both the patient and the provider [59], that
individuals with HD often do not discuss these concerns with physicians [60], that
physicians often neglect to initiate discussions about EOL options with patients [61; 62], and
that this has been recognized as a priority area for HD clinical care [10; 60; 61; 63], these
measures may serve as a catalyst to help initiate these difficult conversations between
patients and providers. Furthermore, scores on these measures may potentially serve as
referents for making appropriate clinical referrals for palliative care services and to identify
distressed individuals who might benefit from consultation with mental health services
and/or pastoral counselors.
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There is no cure for HD; thus, all HD care is essentially palliative. There are many evidencebased palliative care interventions available to increase HRQOL of persons with HD [4-7].
However, denial, stigma, and conflicting family perceptions of what constitutes quality of
life and a “good death” are barriers to engaging in EOL discussions [64]. HD has some
unique characteristics that make disease-specific EOL measures critical. Since HD is an
autosomal dominant genetic disorder (i.e., it runs in families), persons with a positive gene
test have often witnessed the decline and death of several family members while they
contemplate their own genetic fate. In addition, people with the HD gene mutation generally
have normal functioning until mid-life when subtle symptoms begin, and then slowly
progress to increasing levels of impairment over 15-20 years or more. Our measures are
designed to evaluate EOL across the entire disease course. This will enable us to better
understand how beliefs about EOL change over time in people with HD, and how they are
impacted by their inevitable cognitive decline. Furthermore, the EOL measures developed
here are suitable for use in later-stage patients, and will help care providers to evaluate the
needs/wants of these individuals in order to provide a supportive environment during the end
of life stage of HD. Current healthcare policies do not provide support for long-term
palliative care [4]. There is also evidence that patients with neurological conditions are less
likely than other types of patients, such as patients with cancer, to make advanced directives
or receive palliative care at the end of life [65]. Our HD-specific EOL measures can help
identify patients who could benefit from palliative care and advance directives decision
making, as well as identify when patients are likely to be most receptive to these
interventions.
While this study has a number of strengths, there are also some limitations. Our study
sample might not be representative of all people with HD. We recruited participants from
Qual Life Res. Author manuscript; available in PMC 2017 October 01.
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specialized HD clinical centers and from the PREDICT-HD study. Most persons with HD do
not have access to specialized HD centers. Participants in the PREDICT-HD study are
persons who have independently chosen to be tested for the HD gene mutation prior to
symptom onset [31-33]. It is estimated that less than 25% of persons at risk for HD undergo
pre-symptomatic genetic testing [66]. Thus, our sample might be more open to discussing
EOL concerns because they have given consideration to their own futures through seeking
HD genetic testing. Previous research in HD has indicated that persons with HD may
demonstrate impaired awareness of their illness state [67]. This could potentially lead to
them reporting fewer concerns with death and dying as the disease progresses, which would
be counterintuitive. Thus, including caregiver perspectives in HD studies is important; a
factor that is not represented by our study design (which focused solely on patient-centered
outcomes). Future studies, especially those examining individuals in the later stages of the
disease, should consider including caregivers. Finally, some study participants completed the
assessments via computers at home and might have received input and assistance from
others while others completed the assessments in a research setting. Future work should
consider examining group differences among these responders.

Author Manuscript

Taken together, these are the first HD-specific measures that have been developed to capture
EOL issues such as meaning of life and concerns about death and dying over the course of
HD. In addition, although these measures were developed for use in HD research, they may
also have utility in the HD clinic, and might be applicable to other conditions that share
similar characteristics, such as early-onset Alzheimer disease (which shares an autosomal
dominant inheritance pattern and a progressive course), as well as other common
neurological diseases that involve behavioral, cognitive, and/or motor symptoms (e.g.
Parkinson disease, Multiple Sclerosis, Alzheimer's disease). Future efforts should focus on
validating these new measures in other terminal conditions.
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Figure 1.

Procedures to develop the new end of life concerns item pool
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Figure 2. HDQLIFE Meaning and Purpose Test Information

In general, we want total information to be > 9.0 and standard error to be < 0.33 (this
provides a reliability of 0.9). This figure shows excellent total information and standard error
for Meaning and Purpose scale scores between −3 and 0.5.
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Figure 3. HDQLIFE Concern with Death and Dying Test Information

This figure shows the test information and scale score standard error for different scale
scores in standard deviation units for the Concern with Death and Dying scale. Information
was good (i.e., reliability ≥ .80), for scale scores between −1.5 and 3.0.
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Figure 4. HDQLIFE Concern with Death and Dying Number of CAT Items by CAT Theta

This figure shows the number of CAT items used for different scale scores in standard
deviation units: at −1 SD units, the CAT always used all 12 items in the item bank; at +1 and
+2 SD units, the CAT always used the minimum number of 4 items in the item bank; and at
3 SD units the CAT used all 12 items in the item bank.
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I am worried about how my family will cope with my death.

I am worried about how my family will deal with my death.

I am concerned with how my death will impact my family.
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How often did you think about your family members that have died from this disease?

I think about my family members who died from the disease.
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There are important things that I still want to do with my life.

End of life planning is important.
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I feel comfortable talking about my death.

I find meaning in my illness.

I am at peace with death.

My life has meaning.

I am at peace with the fact that I will die.
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I am satisfied with my decisions about my healthcare.
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Exploratory Factor Analysis Results for the HDQLIFE End of Life Concerns Item Pool
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Note.

I am concerned that I won't be able to have children.

I feel in control of my life.

a

In the past 7 days to what degree did you have to push yourself to keep going?

I think about how I will die.

In the past 7 days how often were you afraid of the future?

In the past 7 days how often were you afraid of dying?

b

In the past 7 days how often were you worried your illness would get worse?

In the past 7 days how often did you become sad when you thought about the end of your life?

In the past 7 days how often did you think about ending your life?

In the past 7 days how often did you talk to others about your own death?

In the past 7 days how often did you feel anxiety that you would die?

In the past 7 days how often were you preoccupied with thoughts of death?

In the past 7 days how often did you think about your own death?

In the past 7 days how often were you preoccupied with thoughts of dying?

In the past 7 days how often did you think about dying?

b

In the past 7 days how often did you feel like a financial burden to your family?

In the past 7 days how often did you worry about how your family would cope with your death?

I worry about my children inheriting this disease.

I am afraid of suffering.

a

In the past 7 days how often did you worry about the emotional burden that your disease places on your family or friends?

I am afraid of what the future holds for me.

I feel like a financial burden to my family.
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Seeing other people with my illness makes me think about my own death.

0.14

0.35

0.07

−0.02

0.08

0.02

−0.05

−0.03

0.25

−0.14

0.00

0.04

0.00

−0.01

−0.02

−0.08

−0.11

0.02

0.14

−0.14

0.14

0.06

0.01

Factor 1

0.18

0.14

0.03

0.15

−0.22

−0.39

0.00

−0.21

0.20

0.13

−0.31

0.00

0.09

−0.03

0.12

0.09

0.06

0.25

−0.18

0.16

−0.13

0.08

0.15

Factor 2

0.15

0.02

0.11

0.22

0.25

0.19

0.22

0.16

−0.21

0.04

0.14

−0.01

0.04

−0.06

−0.03

0.34

0.45

0.46

0.51

0.52

0.54

0.56

0.63

Factor 3

Author Manuscript

End of Life Concerns Items

0.08

0.40

0.45

0.58

0.63

0.64

0.65

0.72

0.74

0.74

0.80

0.90

0.90

0.94

0.97

0.46

0.48

−0.03

0.19

0.37

0.29

0.25

0.16

Factor 4

Carlozzi et al.
Page 20

Author Manuscript
response options = never, rarely, sometimes, often, always.

b

response options = not at all, a little bit, somewhat, quite a bit, very much

Author Manuscript

a
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−2.26
−2.78

2.64
2.26
0.91

I am making the most out of the time I have left.

My life has meaning.

I find meaning in my illness.

−1.87
−1.91

3.66
4.75

I am satisfied with my ability to make the most out of the time that I have left.

I live my life to the fullest.

Note. Items that are bolded were selected for inclusion in the final, 4-item short form

−3.26

1.30

There are important things that I still want to do with my life.

−1.27

−2.72

0.84

I feel comfortable talking about my death.

T1

Slope

Item

−1.48

−1.40

−2.44

−0.64

−2.13

−1.68

−1.60

T2

−0.65

−0.71

−1.28

0.69

−1.11

−0.83

−0.10

T3

0.11

0.01

−0.34

1.78

−0.26

−0.01

1.21

T4

Author Manuscript

HDQLIFE Meaning and Purpose Item Parameters
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1.28

0.32
0.17

1.48
2.21
4.55
2.50

In the past 7 days how often did you think about ending your life?

In the past 7 days how often did you become sad when you thought about the end of your life?

In the past 7 days how often were you preoccupied with thoughts of dying?

In the past 7 day how often did you feel anxiety that you would die?

−0.61
−0.90

1.62
1.77
3.64
1.59
1.82
1.98

In the past 7 days how often did you talk to others about your own death?

In the past 7 days how often were you worried your illness would get worse?

In the past 7 days how often were you preoccupied with thoughts of death?

In the past 7 days how often did you worry about how your family would cope with your death?

In the past 7 days how often were you afraid of the future?

I think about how I will die.

Note. Items that are bolded were selected for inclusion on the 6-item short form.

0.37
−0.65

4.57

In the past 7 days how often did you think about your own death?

−0.98

0.28

0.12
−0.02

4.57

In the past 7 days how often did you think about dying?

−0.07

T1

Slope

Concern with Death and Dying Item

0.20

0.12

0.12

1.02

−0.19

1.27

0.80

0.84

0.87

1.00

0.59

2.02

T2

Author Manuscript

HDQLIFE Concern with Death and Dying Item Parameters

1.56

1.20

1.07

1.81

0.83

2.57

1.61

1.60

1.70

1.71

1.52

2.73

T3

2.21

2.13

1.73

2.41

1.57

3.65

2.18

2.23

2.24

2.18

2.12

3.38

T4

Author Manuscript

Table 3
Carlozzi et al.
Page 23

Qual Life Res. Author manuscript; available in PMC 2017 October 01.

Carlozzi et al.

Page 24

Table 4

Author Manuscript

HDQLIFE Meaning and Purpose SF Summed Score to t Score Conversion Table
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Meaning and Purpose SF Summed Score

Meaning and Purpose t Score

4

22

5

25

6

27

7

29

8

31

9

33

10

35

11

37

12

39

13

40

14

42

15

44

16

46

17

48

18

51

19

54

20

61

Note. SF = 4-item Short Form
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Table 5
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HDQLIFE Concern with Death and Dying SF t Score Conversion Table
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Death and Dying SF Summed Score

Death and Dying t Score

6

36

7

41

8

44

9

46

10

48

11

51

12

52

13

54

14

56

15

57

16

59

17

60

18

61

19

63

20

64

21

65

22

67

23

68

24

70

25

71

26

73

27

74

28

76

29

77

30

80

Note. SF = 6-item Short Form
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